Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development

Karin Seifert*

London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK

Abstract: Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002. Combination therapy is now explored in clinical trials as a new treatment approach for VL to reduce the length of treatment and potentially prevent selection of resistant parasites. However there is still a need for new drugs due to safety, resistance, stability and cost issues with existing therapies. The search for topical treatments for cutaneous leishmaniasis (CL) is ongoing. This review gives a brief overview of recent developments and approaches in anti-leishmanial drug discovery and development.

Keywords: Leishmaniasis, drug discovery, drug development.

LEISHMANIASIS

Leishmaniasis is a disease complex caused by protozoan parasites of the genus Leishmania. Parasites are transmitted by female sandflies via anthropocentric or zoonotic cycles [1]. Leishmania parasites have a dimorphic life-cycle; promastigotes develop in the gut of female sandflies to infectious forms that are transmitted to mammalian hosts [2,3]. Inside the host parasites survive and multiply as amastigotes within parasitophorous vacuoles (PVs) of macrophages [4,5]. Main clinical manifestations include visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL) and rarer manifestations such as mucosal leishmaniasis and post-kala-azar dermal leishmaniasis (PKDL). An estimated 350 million people are at risk of infection and disease worldwide. The annual incidence is estimated at 1.5 - 2 million with 70 000 deaths each year [1]. However due to underreporting and misdiagnosis actual case loads are expected to be higher. Leishmaniasis is included in the neglected tropical diseases (NTDs) [6] and a strong link to poverty is recognized [7]. Epidemiology, pathogenesis, diagnosis and disease control have recently been reviewed [1,8].

DRUGS AVAILABLE AND IN CLINICAL TRIALS

The following paragraphs provide an overview of currently used and clinically investigated anti-leishmanial drugs. Consideration is given to clinical data, reported toxicities and pharmacokinetics (PKs), chemistry, their mode of action (MOA) and cellular targets.

Pentavalent Antimonials

Pentavalent antimonials (meglumine antimonate (MA) and sodium stibogluconate (SSG)) have been used in the treatment of VL and CL for more than 60 years. Response rates are still over 95% in previously untreated VL patients in many parts of the world, but acquired resistance to pentavalent antimony (Sb⁵⁺) has developed in the high-prevalence, high-transmission epidemic region of Bihar, India [9]. Failure rates of 65% have been reported and the use of antimony abandoned in this region [10]. Other issues related to treatment include confirmation of drug efficacy, side effects of low-cost generic drugs and lot-to-lot variation [11]. Cardiotoxicity has been reported as drug-induced effect [12,13]. Serious cardiotoxicity is seen in 9-10% of treated patients. Higher rates have been reported due to improper formulation of drug and use of lots with high osmolarity [13]. Pharmacokinetics of pentavalent antimonials has been described by a two compartment, three term pharmacokinetic model. An initial absorption phase was followed by a rapid elimination phase (mean half-life 2.02h) and a slow elimination phase (mean half-life 76 hours) in patients treated with MA or SSG [14]. In infected dogs treated with multiple doses of MA an absorption phase was followed by a rapid disposition phase (half-life α 1.41 hours) and a slower terminal phase (half-life β 8.76 hours) [15].

The chemical structure and composition of meglumine antimonate and sodium stibogluconate have recently been re-evaluated by electrospray ionization mass spectrometry (ESI-MS) and osmolarity measurements [16]. The authors reported that MA and SSG consist as mixtures of 2:2, 2:3 and 2:1 Sb⁵⁺-ligand complexes in concentrated aqueous solutions. Increasing depolymerisation occurs with increasing dilution and conversion of the highly aggregated state into dissociated complexes and antimonate is expected in human serum after drug administration. 1:1 Sb⁵⁺-ligand complexes, together with antimonate, are expected to be the final Sb⁵⁺ form of these drugs and pharmacologically relevant [16].

Pentavalent antimonials are now generally accepted as prodrugs which require reduction to the trivalent form for...
Amphotericin B

Amphotericin B is a polyene antibiotic, which was originally extracted from Streptomyces nodosus. Crystalline amphotericin B is insoluble in water and different formulations are available. Amphotericin B deoxycholate (Fungizone®), a micellar formulation, is highly effective. It is used as first line treatment in areas with high rates of unresponsiveness to antimonials and second line treatment elsewhere [11]. Lipid based formulations of amphotericin B are available and liposomal amphotericin B (AmBisome®) has been approved for treatment of VL by the U.S. Food and Drug Administration (FDA) [20]. Shorter treatment courses and single dose regimens of liposomal amphotericin B have been investigated in the state of Bihar, India [21-23]. The most recent study tested the efficacy of liposomal amphotericin B at a single dose of 10 mg/kg in comparison to 15 alternate-day infusions of amphotericin B deoxycholate at a dose of 1mg/kg. Single dose liposomal amphotericin B was not inferior to and less expensive than amphotericin B deoxycholate, but a non-significantly higher relapse rate was noted in the liposomal treatment group [24]. Other commercially available lipid formulations, amphotericin B lipid complex (ABLC) and amphotericin B colloidal dispersion (ABCD) have also been tested for treatment of VL [25]. A commercially standardized product of amphotericin B deoxycholate premixed with lipid emulsion containing egg lecithin and soyabean oil (ABLE) is licensed in India for the use of VL. However overall cure rates in phase II clinical trials in India using this formulation as monotherapy were lower than the desired cure rate of approximately 95% [26,27].

Need for hospitalization, constant monitoring of patients, prolonged duration of treatment and infusion-related adverse events (fever, chills, trombophlebitis) are drawbacks of amphotericin B deoxycholate. Toxicities such as hypokalaemia, nephrotoxicity and myocarditis can occur [12]. Liposomal amphotericin B is much safer than amphotericin B deoxycholate and also highly efficacious [11,12]. However high cost limits widespread use in many VL-endemic regions. Recently new preferential pricing was agreed for certain countries with a cost of $20 per 50 mg vial of AmBisome® [28]. In liposomal amphotericin B drug is formulated with cholesterol and other phospholipids within a small unilamellar liposome. Temperatures of >25°C and <0°C can alter liposome characteristics and may impact on efficacy and toxicity of liposomal amphotericin B [29]. ABLE is stable at higher temperatures for a certain time.

Characteristics that increase efficacy and minimize toxicity of liposomal amphotericin B are effective tissue penetration with sustained levels and stability in blood, macrophages and tissues [29]. Tissue penetration is highest in liver and spleen. Preclinical pharmacokinetics of AmBisome® has been studied in mice, rats, rabbits and dogs. Its mean elimination half-life ranges from 5-24 hours depending on dose and species [30]. In humans the terminal elimination half-life after repeated administration of liposomal amphotericin B has been reported with around 7 hours [31]. Longer half-lives have been reported with increased sampling times, but reported data in Leishmaniasis patients is limited. A study on L. infantum infected mice treated with multiple doses of AmBisome® also found high levels of the drug in liver and spleen [32].

Selectivity of amphotericin B against Leishmania is due to higher affinity of amphotericin B for 24-substituted sterols, the predominant sterol in Leishmania membranes, over cholesterol, the predominant sterol in mammalian cells. Interaction with membranes leads to formation of transmembrane amphotericin B channels, aqueous pores, and leakage of cations [33,34]. Selectivity and toxicity is also linked to the aggregation state of amphotericin B [34].

Miltefosine

Miltefosine is an alkylphosphocholine, originally developed as anti-cancer drug. It was the first oral anti-leishmanial drug that reached the market and is registered for treatment of VL in India and Germany and for CL in Colombia. It is used as potential tool in the elimination programme in India, Bangladesh and Nepal and as second line treatment for CL in Colombia and Bolivia [11].

General safety findings indicate the gastrointestinal tract as main target organ of side-effects [35]. Gastrointestinal symptoms were also recognized as the most common adverse effect in clinical trials [36]. Transient moderate elevation of hepatic enzymes was also observed. In a recent phase 4 study and in previous trials adverse events occurred more frequently in the first week of treatment and decreased with time [36]. The major limitation of miltefosine is its contraindication in pregnancy and mandatory contraception for women in child-bearing age for the duration of therapy and 2-3 months beyond. This restriction is based on a teratogenic effect seen in one species (rat) in preclinical studies [35] and the pharmacokinetic profile of miltefosine.

A recent study described the pharmacokinetics of miltefosine by a two-compartment disposition model with a first elimination half life of 7.05 days and a terminal half-life of 30.9 days in CL patients after treatment with 50 mg miltefosine three times daily for a total of 28 days [37]. A long terminal half-life of 150 – 200 hours has previously been reported and concerns were raised that subtherapeutic levels of miltefosine in the body after completion of treatment might contribute to the emergence of resistance [38]. In the laboratory Leishmania promastigotes resistant to miltefosine concentrations of up to 40µM were easily generated and resistance was conferred to the intracellular amastigote stage [39,40].

Uptake of miltefosine into L. donovani is mediated by a plasma membrane P-type ATPase aminophospholipid translocase [41-43]. Suggested targets of miltefosine in Leishma-
nia include perturbation of ether-lipid metabolism, glycosyl-phosphatidylinositol (GPI) anchor biosynthesis and signal transduction [44] as well as inhibition of the glycosomal located alkly-specific acyl-Co-A acyltransferase, an enzyme involved in lipid remodeling [45]. Recently mitochondria and specifically the cytochrome c oxidase have been implicated as target of miltefosine in \textit{L. donovani} promastigotes [46]. Effects on lipid metabolism, specifically phospholipid content, fatty acid and sterol content, have also been described in \textit{L. donovani} promastigotes [47].

**Paromomycin**

Paromomycin, an aminoglycoside antibiotic, is the latest anti-leishmanial drug registered for VL in India. In a randomized, controlled, phase 3 study in India paromomycin was shown to be noninferior to amphotericin B with a final cure rate of 94.6\% versus 98.8 \% [48]. A recent study compared 11mg/kg/day of paromomycin for 14 days to 11mg/kg/day of paromomycin for 21 days in Indian VL. The definite cure rate in the short-course treatment group of 14 days was significantly lower than the rate in the 21 day treatment group (82\% versus 92\% based on intention-to-treat analysis) [49].

Paromomycin has also been formulated for topical treatment of CL [11,50]. It is used as topical treatment for CL in Israel in a methylbenzethonium chloride ointment (Leshcutan) [50]. Recently a phase 2, placebo controlled study, carried out in Tunisia and France, reported efficacy (cure rate 94\%) and safety of the third generation aminoglycoside ointment WR279,396, a hydrophilic formulation of 15\% paromomycin plus 0.5\% gentamicin [51]. Local treatment of CL in the form of topical formulations offer the advantage of ease of administration, fewer side effects and cost-effectiveness in comparison to systemic treatment [52].

Injection-site pain was the most frequently reported adverse event in the phase 3 trial for VL in India [48]. Otoxicity and nephrotoxicity are known drug class effects, but frequency of these reactions has been reported as low at therapeutic dosages for VL [50]. Otoxicity in a small percentage of patients in the recent phase 3 trial was reported as transient and reversible and the drug had a reasonable safety profile [48]. Monitoring of hepatic enzyme levels was recommended in the recent short-course trial [49].

Pharmacokinetic data has been reported from VL patients during the phase 3 trial. Paromomycin was absorbed quickly after intramuscular injection. Peak plasma levels were reached within 1 hour. Plasma levels 1 hour after injection ranged from 18.3 µg/ml to 20.5 µg/ml and trough plasma levels at 24 hours after injection from 1.31 µg/ml to 4.53 µg/ml. Plasma levels on days 1, 8, 15, 21 and 22 were similar [48]. Population estimates for absorption and elimination half-lives have been reported as 0.33 hours and 2.62 hours [50]. Pharmacokinetic data following a single intramuscular dose of paromomycin in healthy adult volunteers has also been reported [53].

Previous studies on paromomycin in \textit{Leishmania} spp. have implicated mitochondrial membrane depolarisation, ribosomes and respiratory dysfunction in the mode of action of this molecule [54-56]. Decreased drug uptake was shown in a paromomycin resistant \textit{L. donovani} line [57]. Some of these findings have been confirmed in a recent study on \textit{L. donovani} promastigotes [58].

**Pentamidine**

Pentamidine is an aromatic diamidine, still in use as first line drug for certain forms of CL. In VL it is used as second-line treatment only due to toxicity and efficacy issues [11]. The major safety concern with pentamidine is induction of insulin-dependent diabetes mellitus and in India its use for VL has been abandoned [12].

Early work has implicated the mitochondrion in the mode of action of pentamidine. Morphological changes with swelling of mitochondria and fragmentation of kinetoplastid DNA were reported in electron microscopy studies on \textit{Leishmania} spp [59,60]. An uncoupling effect on mitochondria \textit{in situ} with collapse of mitochondrial membrane potential was shown in \textit{L. donovani} promastigotes [61]. Alkalisation of acidocalciosomes of \textit{L. donovani} promastigotes has also been reported [62]. In a recent study mitochondria have been suggested as site of pentamidine accumulation in \textit{L. donovani} and drug resistance associated with mitochondria alterations [63]. Pentamidine enters promastigotes and amastigotes of \textit{Leishmania} via a carrier mediated process which recognizes diamidines with high affinity [64].

**Sitamaquine**

Sitamaquine (WR6026) is an 8-aminoquinoline currently in clinical development by Glaxo Smith Kline for oral treatment of VL [65]. Discovery of sitamaquine as anti-leishmanial agent was based on extensive efforts in synthetic chemistry at the Walter Reed Army Institute for Research (WRAIR) [66]. Recently results were reported from phase II dose ranging studies in India and Kenya. The overall cure rate at day 180 in the intention-to-treat-population was 83\% in Kenyan patients [67] and 87\% in Indian patients [68]. Abdominal pain and headache were reported in the Kenyan study and vomiting, dyspepsia and cyanosis by the Indian investigators. Methemoglobinemia is associated with 8-aminoquinolines, but was only reported in Indian patients [68].

Studies using rat and hamster liver microsomes have identified two major metabolites of sitamaquine, the desethyl and 4-CH₂OH derivatives, with evidence of cytochrome P-450 mediation [65,69]. Side chain oxidation and 5-hydroxylation have been identified as important steps in the metabolic pathway of 8-aminoquinolines [65,70]. Pre-systemic elimination of sitamaquine in the liver with low systemic availability was observed in Beagle dogs [71]. The elimination half-life of sitamaquine in humans is reported as 26.1 hours. The major urinary metabolite in humans is the 4-CH₂OH derivative with a reported elimination half-life of 29.1 hours. A minor metabolite in humans is the desethyl species [65]. Metabolites may be linked to efficacy and toxicity of this compound.

Sitamaquine induced morphological changes in intracellular \textit{L. tropica} amastigotes and host macrophages [59]. Collapse of mitochondrial membrane potential in \textit{L. donovani} promastigotes has also been shown [61] as well as alkalisa-
tion of acidocalcisomes [62]. Recently anti-leishmanial ac-

tivity has been demonstrated as unrelated to sitamaquine
accumulation in this organelle [72]. The interaction of si-
tamaquine with membrane lipids of *L. donovani* promas-
tigotes has been assessed and described as a two-step process
[73].

Chemotherapy and its role in treatment and control of
leishmaniasis has recently been reviewed [11]. Treatment
regimes of first and second line drugs against VL and CL
and route of administration have been described [11,74].

RECENT DEVELOPMENTS AND SELECTED DRUG

CLASSES – FROM DISCOVERY TO PRECLINICAL

STAGES

The following paragraphs describe some new develop-
ments at the discovery and development stage. These include
new compounds and new formulations of compounds and
drugs for which *in vivo* efficacy has been demonstrated in
relevant animal studies.

2-Substituted Quinolines

2-substituted quinoline alkaloids were originally isolated
from a Bolivian medicinal plant (*Galipea longiflora* Kr, Ru-
taceae) and shown to have an effect in the treatment of ex-
perimental New World CL [75]. Activity of 2-substituted
quinoline alkaloids was subsequently reported in the *L.
donovani* – BALB/c mouse model with 2-n-propylquinoline
showing significant activity after oral administration and
chimanine D after subcutaneous administration [76]. Recent
structure activity relationship (SAR) studies on a series of 2-
substituted quinolines concluded that the most active quino-
lines against intra-macrophage *L. infantum* and *L. ama-
zonensis* amastigotes *in vitro* had a three carbon alkenyl side
chain with reactive electrophilic functions such as carbonyl,
hydroxyl or halogen [77]. Significant efficacy of selected
compounds was demonstrated in *L. amazonensis* and *L.
donovani* infected BALB/c mice after oral administration.
One compound emerged as the single compound with satis-
factory activity across the *in vivo* models employed, contain-
ing a propenyl chain functionalized by an -OH group [78].
Biotransformation of this and other 2-substituted quinolines and
their *in vitro* behavior in the blood compartment was stud-
ied showing discrepancies of affinity to erythrocytes
amongst this series [79,80].

8-Aminoquinolines

8-aminoquinolines were originally developed as anti-
malarials, but have also shown promise in the treatment of
leishmaniasis as seen with sitamaquine (WR6026, lepidine).

Another 8-aminoquinoline, NPC1161, has shown activity
against *L. donovani* in *in vivo* in a similar order of magnitude
to sitamaquine when tested as (-) enantiomer. Clear stereoelec-
tive differences in drug activity and toxicity were shown for
this compound when tested as racemate, (-) or (+) enantiomer
in the same study [81]. Synthesis and *in vitro* activities of
other 8-aminoquinolines against *L. donovani* promastigotes
have been reported [82,83]. These include derivatives with a
5-(3-trifluoromethylenoxy) substitution on the quinoline
ring and methyl-substituted, ethyl-substituted or unsubsti-
tuted C4 positions [82]. Notably the 5-(3-trifluoromethyl-

phenoxy) substitution is also part of tafenoquine, another 8-
aminoquinoline with anti-parasitic activity [66].

Buparvaquone and Derivatives

Buparvaquone is a hydroxynaphtoquinone, which is cur-
rently marketed as Butalex® for the treatment of theileriosis
in cattle. It was demonstrated as being highly active *in vitro*
against intracellular *L. donovani* amastigotes in macro-
phages, but less active *in vivo* in the BALB/c mouse [84]. Its
potent *in vitro* activity was recently confirmed against a
range of *Leishmania* spp. with EC₅₀ Values for the intracellu-
ar amastigote stage in the low micromolar to nanomolar
range [85]. The same study investigated water soluble phos-
phate prodrugs of buparvaquone and reported potent *in vitro*
activity against CL and VL causing *Leishmania* species [85].
Buparvaquone oxime derivatives were also investigated, but
displayed lower *in vitro* activity against *L. donovani* than the
parent compound [86]. The prodrug approach is an effective
way of improving oral bioavailability of poorly soluble drugs
by chemical derivatization to more water soluble com-
pounds. It is also used to improve topical drug delivery.
Formulations for topical delivery of buparvaquone and a
prodrug (3-phosphono-oxyethyl-buparvaquone) have been
developed and characterized in *in vitro* human and mouse
skin models [87]. Efficacy of topical formulations and phos-
phate prodrugs of buparvaquone in *in vivo* models of VL and
CL has been reported [88].

New Amphotericin B Formulations

Recently a number of new amphotericin B formulations
with high anti-leishmanial activity *in vivo* have emerged.
The main focus of the re-formulation of this highly active
molecule is to increase solubility and thermal stability and
decrease systemic toxicity of amphotericin B. A reduced cost
of new amphotericin B formulations is also desired. Solid
nanoparticles of amphotericin B deoxycholate have shown
activity after intraperitoneal injection into *L. donovani*
injected hamsters with 99% suppression of parasite replication
in the spleen at a dose of 5mg/kg/day given for 5 days [89].
A novel lipid based amphotericin B formulation has recently
been reported as active after oral administration in *L. dono-
vanii* infected mice. Parasitemia in the liver was inhibited by
99.5% and 99.8% at doses of 10 and 20 mg/kg twice daily
for 5 days [90]. N-(2-hydroxypropyl)-methacrylamide-
GFLG-amphotericin B copolymer conjugates inhibited para-
sitemia by up to 94% in the liver of *L. donovani* infected
BALB/c mice after intravenous administration of 1mg/kg
amphotericin B equivalent on 3 alternate days and by up to
99.6% at a dose of 3mg/kg amphotericin B equivalent [91].
This approach was extended to investigate poly(HPMA)-
GFLG-amphotericin B-alendronic acid conjugates as poten-
tial combination therapeutics in models of VL [92].

RECENT DEVELOPMENTS – CLINICAL AND USE
OF ANTI-LEISHMANIAL DRUGS

The following paragraph describes new developments in
the use of anti-leishmanial drugs available to patients. These
include new treatment regimes in the form of combination
chemotherapy or co-administration of drugs.
**Combination Chemotherapy**

Advances in anti-leishmanial chemotherapy including the development of new drugs have made combination chemotherapy a real possibility. Multi-drug therapy is already standard practice in the treatment of other infectious diseases such as tuberculosis, leprosy and malaria [93-96]. Drug combinations aim to delay or prevent the emergence of resistance, shorten the course of treatment and lower required doses. Other potential advances include convenience, better compliance and lower costs [97]. A combination regime of sodium stibogluconate and paromomycin is currently employed in Sudan by Médecins sans frontiers (MSF) [98]. Single dose liposomal amphotericin B forms part of a new treatment approach for VL. A single dose of liposomal amphotericin B was followed by a short-course treatment of miltefosine for 7 - 14 days in a recent study in India. Results were satisfactorily with cure rates >95% in the different treatment groups [97]. Further trials that investigate single dose liposomal amphotericin B followed by short treatment courses of miltefosine or paromomycin and the combination of miltefosine and paromomycin are completed, as is a trial investigating the combination of sodium stibogluconate and paromomycin (http://clinicaltrials.gov, accessed March 28th 2010).

**DRUG TARGETS IN LEISHMANIA AND CHEMICAL STRUCTURES**

The following paragraphs describe potential drug targets in *Leishmania* with classes of chemical inhibitors where applicable and chemical structures for which a target has been demonstrated or a hypothesized target was starting point of the studies.

**Drug Targets**

Protein kinases are key regulatory proteins and represent a drug target in *Leishmania* and other trypanosomatids. Mitogen-activated protein kinases (MAP kinases), LmxMPK1 (*Leishmania mexicana*) mitogen-activated protein kinase 1) and LmxMPK2 have been found essential for survival of amastigotes in infected hosts or the establishment of infections in mice [99]. Cyclin-dependent kinases have been chemically validated as potential drug targets by systematic analysis of chemical inhibitors. Thus *L. mexicana* CRK3 was screened against a chemical library of potential inhibitors and potent CRK3 inhibitors screened against intracellular *L. donovani* amastigotes in vitro. The most potent inhibitors were found to belong to the indirubin class of chemicals, others were 2, 6, 9-trisubstituted purines, paullones and derivatives of the non-specific kinase inhibitor staurosporine [100]. Recently 6-bromo substituted indirubins were reported as highly active in vitro against *L. donovani* and their action linked to CRK3 and GSK-3, a serine/threonine kinase [101]. Essentiality of protein kinases for proliferation and/or viability of the parasite and significant sequence differences from mammalian homologues are important points. The role of protein kinases as drug targets has been reviewed [102]. Currently the kinome of *Leishmania* is investigated in anti-leishmanial drug discovery [103].

Proteases (peptidases) are also explored and characterized as potential drug target in *Leishmania* [104,105].

**Chemical Structures**

Pentamidine analogues and aromatic diamidines are still of interest in anti-leishmanial integrating drug screens. Structure activity relationships (SAR) of synthetic compounds have recently been reported [106,107]. Binding of diamidines to DNA has been described and characterized [108].

Azasteroles are nitrogen containing sterol compounds. Azasterols with a nitrogen in the side chain of sterols at the 23-, 24-, or 25-position can inhibit the enzyme delta24-sterol methyltransferase (24-SMT) in fungi and plants and inhibit sterol biosynthesis [109]. A series of azasterols with and without protection at the C-3 of the sterol nucleus has been assessed, but multiple modes of action were found against *Leishmania* spp. *In vitro* activity of C-3 protected azasterols was reported against intracellular *L. donovani* amastigotes [109]. *In vitro* activity was also reported for transition state analogues of 24-SMT [110]. A recent SAR study by the same group on new series of azasterols provided further insights into the pharmacophore of these compounds against *L. donovani* [111]. Their mode of action remains unclear.

Quinuclidine derivatives have shown *in vitro* activity against *L. donovani* axenic amastigotes. They act as leishmanial squalene synthetase inhibitors disrupting endogenous sterol biosynthesis [112].

**APPROACHES AND STRATEGIES IN ANTI-LEISHMANIAL DRUG DISCOVERY AND DEVELOPMENT**

Different approaches are used in drug discovery with molecular-target based approaches and exploratory drug screening at both ends of the spectrum. Molecular approaches, whole cell based approaches and a compromise approach between the two have their own values in anti-parasitic drug discovery [113-115]. Criteria for target assessment and different target validation methods have recently been described [113]. An open access database for tropical diseases has been established to merge data from genome sequencing and functional genomics projects, protein structural data and provide information on target essentiality and druggability [115,116].

The development process is guided by target product profiles (TPP), a list of key attributes for potential new drugs [113,117]. For leishmaniasis these attributes entail activity against VL and CL, short treatment courses, injectable agent with reduced treatment time, the desire for an oral drug, an improved safety profile, costs less than current treatment, stability under tropical conditions, the desire for a topical application for CL and the potential to combine with existing agents [117]. Definitions for “hit” and “lead” along with hit-to-lead identification criteria and lead optimization and candidate selection criteria have been summarized. These can be used complementary to the TPP in decision making on further progression of compounds in the development process [118].

A number of new public-private partnerships, non-profit organizations and consortia have been established in recent years to increase support of drug discovery and development for neglected and parasitic or tropical diseases. These include
the Drugs for Neglected Diseases Initiative (DNDi) and The Consortium for Parasitic Drug Development (CPDD). Philanthropic organizations (including the Bill and Melinda Gates Foundation) and governments are also lending increased (financial) support [114-119]. Long standing programmes such as the TDR Screening Network are continued and have evolved to address the need of different stages and aspects in the drug discovery and development process. These include target selection, medicinal chemistry and drug metabolism and pharmacokinetics (DMPK) [117,118]. The integration of these aspects and new technologies, either within an initiative or as networks of partners with complementary expertise is important to sustain and feed the development pipeline.

CONCLUSION

In recent years advances have been made in the treatment of leishmaniasis. New drugs and treatment regimes are available or on the way to availability. The approach to drug discovery and development has also changed and advanced to include and integrate aspects as outlined above. The need to search for better, safer and simpler treatments continues.

ACKNOWLEDGEMENTS

The author thanks Prof. Simon Croft and Dr. Philippe Loiseau for reading of the manuscript. The author is funded by the European Community (FP7).

REFERENCES

[1] Reithinger, R.; Dujardin, J. C.; Louzir, H.; Pirmez, C.; Alexander, B.; Brooker, S. Cutaneous leishmaniasis. Lancet Infect. Dis., 2007, 7, 581-96.
[2] Bates, P. A. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int. J. Parasitol., 2007, 37, 1097-106.
[3] Rogers, M. E.; Ilg, T.; Nikolaev, A. V.; Ferguson, M. A.; Bates, P. A. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of IPPG. Nature, 2004, 430, 463-7.
[4] Burchmore, R. J.; Barrett, M. P. Life in vacuoles—nutrient acquisition by Leishmania amastigotes. Int. J. Parasitol., 2001, 31, 1311-20.
[5] Handman, E.; Bullen, D. V. Interaction of Leishmania with the host macrophage. Trends Parasitol., 2002, 18, 332-4.
[6] Seifert, K.; Pommier, Y.; Corbin, G.; Cartron, G.; Bréchet, P.; Ballet, M.; Misrahi, M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol., 2007, 5, 873-82.
[7] Croft, S. L.; Sundar, S.; Fairlamb, A. H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev., 2006, 19, 111-26.
[8] Sundar, S.; More, D. K.; Singh, M. K.; Singh, V. P.; Sharma, S.; Makharia, A.; Kumar, P. C.; Murray, H. W. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis., 2000, 31, 1104-7.
[9] Alvar, J.; Croft, S.; Olliaro, P. Chemotherapy in the treatment and control of leishmaniasis. Adv. Parasitol., 2006, 61, 223-74.
[10] Olliaro, P. L.; Gérardin, P.; Gersdorff, S.; Haas, J. A.; Rottingen, J. A.; Sundar, S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect. Dis., 2005, 5, 763-74.
[11] Sundar, S.; Sinha, P. R.; Agrawal, N. K.; Srivastava, R.; Rainey, P. M.; Berman, J. D.; Murray, H. W.; Singh, V. P. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolality lot of sodium antimony gluconate. Am. J. Trop. Med. Hyg., 1998, 59, 139-43.
[12] Chulay, J. D.; Fleckenstein, L.; Smith, D. H. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg., 1988, 82, 69-72.
[13] Valladares, J. E.; Riera, C.; Alberola, J.; Gallego, M.; Portus, M.; Cristofol, C.; Franquelo, C.; Arboix, M. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Vet. Parasitol., 1998, 75, 33-40.
[14] Berman, J. D.; Waddell, D.; Hanson, B. D. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob. Agents. Chemother., 1985, 27, 916-20.
[15] Berman, J. D.; Galllauze, J. V.; Best, J. M. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem. Pharmacol., 1987, 36, 197-201.
[16] Seifert, K.; Cunningham, M. L.; Fairlamb, A. H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem., 2004, 279, 39925-32.
[17] Meyendorff, A. S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis., 1999, 28, 42-8; discussion 49-51.
[18] Sundar, S.; Mehta, H.; Suresh, A. V.; Singh, S. P.; Rai, M.; Murray, H. W. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin. Infect. Dis., 2004, 38, 377-83.
[19] Sundar, S.; Agrawal, G.; Rai, M.; Makharia, M. K.; Murray, H. W. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ, 2001, 323, 419-22.
[20] Sundar, S.; Hja, T. K.; Chakup, C. K.; Mishra, M.; Singh, V. P.; Buffels, R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis., 2003, 37, 800-4.
[21] Sundar, S.; Chakravarty, J.; Agrawal, D.; Rai, M.; Murray, H. W. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med., 2010, 362, 504-12.
[22] Sundar, S.; Mehta, H.; Chhabra, A. Singh, S.; Chauhan, V.; Desjeux, P.; Rai, M. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin. Infect. Dis., 2006, 42, 608-13.
[23] Sundar, S.; Singh, A.; Agrawal, D.; Rai, M.; Agrawal, N.; Chakravarty, J.; Safety and efficacy of high-dose infusions of a preformulated amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am. J. Trop. Med. Hyg., 2009, 80, 700-3.
[24] Sundar, S.; Chakravarty, J.; Agarwal, D.; Shah, A.; Agrawal, N.; Rai, M. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop. Med. Int. Health., 2008, 13, 1208-12.
[25] Olliaro, P.; Darley, S.; Laxminarayan, R.; Sundar, S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop. Med. Int. Health., 2009, 14, 918-25.
[26] Bern, C.; Adler-Moore, J.; Berenguer, J.; Boelaert, M.; den Boer, M.; Davidson, R. N.; Figueras, C.; Gradoni, L.; Kafetzis, D. A.; Roels, H.; Rutten, J.; Sauerwein, W. R.; Alvar, J. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Clin. Infect. Dis., 2000, 31, 21-30.
[27] WHO, Report of a WHO informal consultation on liposomal amphotericin B in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 2007, 101, 497-504.
[28] WHO/CDS/NDD/MEM/2007.4
[29] WHO, Report of a WHO informal consultation on liposomal amphotericin B in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 2007, 101, 497-504.
[30] WHO, Report of a WHO informal consultation on liposomal amphotericin B in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 2007, 101, 497-504.
Delta-sterol-methyltransferase (ERG6) from *Leishmania donovani* and characterization of mRNAs in wild-type and amphotericin B-resistant promastigotes. *Antimicrob. Agents Chemother.*, 2004, 48, 2409-14.

[Brajburg, J.; Bolard, J. Carrier effects on biological activity of amphotericin B. *Clin. Microbiol. Rev.*, 1996, 9, 512-31.]

[Sindermann, H.; Engel. Development of miltefosine as an oral treatment for leishmaniasis. *Trans. R. Soc. Trop. Med. Hyg.*, 2006, 100 Suppl 1, S17-20.]

[Bhattacharya, S. K.; Sinha, P. K.; Sundar, S.; Thakur, C. P.; Jha, T. K.; Pandey, K.; Das, V. R.; Kumar, N.; Lal, C.; Verma, N.; Singh, V. P.; Ranjan, A.; Verma, R. B.; Anders, G.; Sindermann, H.; Ganguy, N. K. Phase 4 trial of miltefosine for the treatment of visceral leishmaniasis. *J. Infect. Dis.*, 2007, 196, 591-8.]

[Dorlo, T. P.; van Thiel, P. P.; Huitema, A. D.; Keizer, R. J.; de Vries, H. J.; Beijnen, J. H.; de Vries, P. J. Pharmacoekinetics of miltefosine in Old World cutaneous leishmaniasis patients. *Antimicrob. Agents Chemother.*, 2008, 52, 2855-60.]

[Bryceson, A. Policy for leishmaniasis with respect to the prevention and control of drug resistance. *Trop. Med. Int. Health.*, 2001, 6, 928-34.]

[Seifert, K.; Matu, S.; Javier Perez-Victoria, F.; Castanys, S.; Gamarro, F.; Croft, S. L. Characterisation of *Leishmania donovani* promastigotes resistant to hexadecylphosphocholine (miltefosine). *Int. J. Antimicrob. Agents.*, 2003, 22, 380-7.]

[Seifert, K.; Perez-Victoria, F. J.; Jettler, M.; Sanchez-Canete, M. P.; Castanys, S.; Gamarro, F.; Croft, S. L. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of *Leishmania donovani* and persists in vivo. *Int. J. Antimicrob. Agents.*, 2007, 30, 229-35.]

[Perez-Victoria, F. J.; Gamarro, F.; Ouellette, M.; Castanys, S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. *J. Biol. Chem.*, 2003, 278, 49965-71.]

[Perez-Victoria, F. J.; Sanchez-Canete, M. P.; Castanys, S.; Gamarro, F. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. *J. Biol. Chem.*, 2006, 281, 23760-75.]

[Perez-Victoria, F. J.; Sanchez-Canete, M. P.; Seifert, K.; Croft, S. L.; Sundar, S.; Castanys, S.; Gamarro, F. Mechanisms of experimental resistance of *Leishmania* to miltefosine: Implications for clinical use. *Drug. Resist. Updat.*, 2006, 9, 26-39.]

[Lux, H.; Hart, D. T.; Parker, P. J.; Klenner, T. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. *Adv. Exp. Med. Biol.*, 1996, 416, 201-211.]

[Lux, H.; Heise, N.; Klenner, T.; Hart, D.; Oppedoes, F. R. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in *Leishmania*. *Mol. Biochem. Parasitol.*, 2000, 111, 1-14.]

[Luque-Ortega, J. R.; Rivas, L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in *Leishmania donovani* promastigotes. *Antimicrob. Agents Chemother.*, 2007, 51, 1327-32.]

[Rakotomanga, M.; Blanc, S.; Gaudin, K.; Chamniane, P.; Loiseau, P. M. Miltefosine affects lipid metabolism in *Leishmania donovani* promastigotes. *Antimicrob. Agents Chemother.*, 2007, 51, 1425-30.]

[Sundar, S.; Jha, T. K.; Thakur, C. P.; Sinha, P. K.; Bhattacharya, S. K. Injectable paromomycin for visceral leishmaniasis in India. *N. Engl. J. Med.*, 2007, 356, 2571-81.]

[Sundar, S.; Agrawal, N.; Arora, R.; Agrawal, D.; Rai, M.; Chakravarty, J. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. *Clin. Infect. Dis.*, 2009, 49, 914-8.]

[Davidson, R. N.; den Boer, M.; Ritmeijer, K. Paromomycin. *Trans. R. Soc. Trop. Med. Hyg.*, 2009, 103, 653-60.]

[Ben Salah, A.; Buffet, P. A.; Morizot, G.; Ben Massoud, N.; Zaataur, A.; Ben Alaya, N.; Hamida, N. B.; El Ahmadi, Z.; Downs, M. T.; Smith, P. L.; Deliagl, K.; Grogol, M. *WR279 396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl. Trop. Dis.*, 2009, 3, e432.]
Recent Approaches in Anti-Leishmanial Drug Discovery and Development

The Open Medicinal Chemistry Journal, 2011, Vol. 5  39

[111] Gigante, F.; Kaiser, M.; Brun, R.; Gilbert, I. H. SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents. Bioorg. Med. Chem., 2009, 17, 5950-61.

[112] Cammerer, S. B.; Jimenez, C.; Jones, S.; Gros, L.; Lorente, S. O.; Rodrigues, C.; Rodrigues, J. C.; Caldera, A.; Ruiz Perez, L. M.; da Souza, W.; Kaiser, M.; Brun, R.; Urbina, J. A.; Gonzalez Pacanowska, D.; Gilbert, I. H. Quinuclidine derivatives as potential antiparasitics. Antimicrob. Agents Chemother., 2007, 51, 4049-61.

[113] Frearson, J. A.; Wyatt, P. G.; Gilbert, I. H.; Fairlamb, A. H. Target assessment for antiparasitic drug discovery. Trends Parasitol., 2007, 23, 589-95.

[114] Renslo, A. R.; McKerrow, J. H. Drug discovery and development for neglected diseases. Nat. Chem. Biol., 2006, 2, 701-10.

[115] Hopkins, A. L.; Witty, M. J.; Nwaka, S. Mission possible. Nature, 2007, 449, 166-9.

[116] Aguero, F.; Al-Lazikani, B.; Aslett, M.; Berriman, M.; Buckner, F. S.; Campbell, R. K.; Carmona, S.; Carruthers, I. M.; Chan, A. W.; Chen, F.; Crowther, G. J.; Doyle, M. A.; Hertz-Fowler, C.; Hopkins, A. L.; McAllister, G.; Nwaka, S.; Overington, J. P.; Pain, A.; Paolini, G. V.; Pieper, U.; Ralph, S. A.; Riechers, A.; Roos, D. S.; Sali, A.; Shammugam, D.; Suzuki, T.; Van Voorhis, W. C.; Verlinde, C. L. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat. Rev. Drug Discov., 2008, 7, 900-7.

[117] Nwaka, S.; Hudson, A., Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov., 2006, 5, 941-55.

[118] Nwaka, S.; Ramirez, B.; Brun, R.; Maes, L.; Douglas, F.; Ridley, R. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl. Trop. Dis., 2009, 3, e440.

[119] Don, R.; Chatelain, E. Drug Discovery for Neglected Diseases: View of a public private partnership. In: Antiparasitic and antibacterial drug discovery. From molecular targets to drug candidates., 2009, Edited by Paul Selzer, (Wiley-VCH Verlag GmbH & Co KGaA, Weinheim), 33-43.